Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Patent
1996-12-13
1998-12-29
Smith, Lynette F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
4241881, 4242041, 4242881, 530395, A61K 3900, A61K 3921, C07K 100, C07K 1400
Patent
active
058537244
ABSTRACT:
The present invention provides a vaccine that can be administered to a mammal to cause immunoprotection in the mammal against a pathogenic organism that has an immunodominant epitope. The vaccine includes a modified form of the antigen in which the immunodominant epitope is located. In this modified form, the immunodominant epitope is immunodampened by any of a number of techniques. Examples of immunodampening techniques include addition of N-linked glycosylation sites, change of the net charge on the epitope, and substitution with a tolerated sequence. The vaccine also includes a pharmacologically acceptable carrier.
REFERENCES:
patent: 5041376 (1991-08-01), Gething et al.
patent: 5585250 (1996-12-01), Garrity et al.
S. Olofsson, et al.; Vaccines 93.; pp. 183-187; "Peripheral Carbohydrate structures engaged in regulation of antigenic properties of HIV-1 gp120".
A. Bolmstedt, et al.; Journal of General Virology; vol. 73, No. 12, Dec. 1992, pp. 3099-3105; "Carbohydrate determinant NeuAc-Galbeta(1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120".
P. Simmonds, et al.; Journal of Virology; vol. 164, No. 12, Dec. 1990; pp. 5840-580; "Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1".
H. Kohler, et al.; Journal of Acquired Immune Deficiency Syndromes; vol. 5, No. 11, Nov. 1992; "Clonal Dominance: Cause for a limited and failing immune response to HIV-1 infection and vaccination".
R. Garrity, et al.; Aids Research and Human Retroviruses; vol. 10, No. SUP1; Aug. 1993; "Introduction of potential N-linked glycosylation sites into the V3 domain of HIV-1 gp120: Effects on virus viability, antigenicity and immunogenicity".
Garrity Robert R.
Goudsmit Jaap
Nara Peter L.
Smith Lynette F.
The United States of America as represented by the Department of
LandOfFree
Dampening of an immunodominant epitope of an antigen for use in does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dampening of an immunodominant epitope of an antigen for use in , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dampening of an immunodominant epitope of an antigen for use in will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1421552